A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

Key Inclusion Criteria:

• Male or nonpregnant female, age ≥18 years to <85 years.

• Body mass index (BMI) ≥18 to <35 kg/m2; weight ≥50 kg at Screening.

• Diagnosed with hypertrophic cardiomyopathy at the time of Screening consistent withcurrent American College of Cardiology Foundation/American Heart AssociationGuidelines

• LVOT peak gradient ≥50 mmHg measured at rest or during the Valsalva maneuver asdetermined by echocardiography at Screening (Part A, B and D oHCM only).

• LVOT peak gradient < 30 mmHg measured at rest and < 50 mmHg measured during theValsalva maneuver as determined by echocardiography at Screening (Part C and D nHCMonly).

• Documented left ventricular ejection fraction (LVEF) ≥0.60 at Screening.

• New York Heart Association (NYHA) Classification II-III at Screening.

• Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) < 85 atScreening.

• NT-proBNP ≥ 300 pg/mL (Part C and D nHCM only).

Key Exclusion Criteria:

• Invasive septal reduction any time prior to Screening.

• Documented current or history of obstructive coronary artery disease at any time ormyocardial infarction any time prior to Screening.

• Significant valvular hear disease (moderate-severe aortic stenosis or regurgitation,moderate-severe mitral stenosis or regurgitation not due to systolic anterior motionof the mitral valve)

• History of LV systolic dysfunction (LVEF < 0.45) or stress cardiomyopathy at anytime.

• Known or suspected infiltrative or storage disorder causing cardiac hypertrophy thatmay mimic HCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LVhypertrophy.

• A history of unexplained syncope or sustained ventricular tachyarrhythmia orsupraventricular tachycardia <180 days prior to Screening.

• A history of sudden cardiac arrest at any time or known appropriate implantablecardioverter defibrillator (ICD) discharge <180 days prior to Screening

• History of permanent AF or atrial flutter. Any episode of documented AF or atrialflutter < 180 days prior to Screening Visit (participants with documented AF oratrial flutter ≥ 180 days prior to Screening require adequate anticoagulation andrate control.)

• Fridericia-corrected QT interval (QTcF) ≥480 ms or any other ECG abnormalityconsidered by the Investigator or Medical Monitor to pose a risk to participantsafety.

• Current or prior use of a cardiac myosin inhibitor <90 days prior to Screening.